- R-Clone Epithelial Stem Cell Cloning Platform: provides high-quality seed cells and addresses the challenge of scalable cell expansion.
- IntelCell Intelligent Cell Platform: enables precise functional enhancement through a modular and standardized gene-editing engineering framework.
- MIX0109 Tissue & Cell Rejuvenation Technology: rejuvenates epithelial stem cells by chemical partial reprogramming to enhance their functional potency and therapeutic potential.
- Chimera Chimeric Animal Model Platform: provides a standardized in vitro to in vivo validation pipeline to confirm product potency relevant to human physiology.
- REGEN-Wukong AI Platform: enables efficacy prediction and improves trial success rates through multi-modal data integration and analysis.
- Specialized Organ-Specific Validation Platforms: provides specialized, high-fidelity in vitro models for our lead therapeutic areas.
R-Clone Epithelial Stem Cell Cloning Platform
The Foundational Engine for Scalable Cell Production
Our R-Clone epithelial stem cell cloning platform is a globally leading technology system that serves as the core engine for our regenerative medicine pipeline. It is specifically designed to address the longstanding challenges in the cell therapy industry by enabling:
1) high-quality seed cells isolation from epithelial tissues; and
2) highly efficient, stable, and scalable in vitro expansion of the isolated epithelial stem/progenitor cells.
The platform innovatively combines a supportive feeder-cell system with a chemically-defined, small-molecule cocktail medium, accurately recapitulating the in vivo niche microenvironment without genetic modification.
This cross-organ applicability is the technical cornerstone of our “one platform, multiple products” strategy, providing a reproducible and scalable core technology for developing more innovative cell therapies across a wide range of serious diseases.
IntelCell Intelligent Cell Platform
Engineering the Next Generation of Smart Therapeutics
The IntelCell platform represents a major advancement beyond traditional cell replacement approaches, enabling intelligent tissue repair and establishing our leadership in precise, controllable, and multifunctional cell therapies.
Built upon the R-Clone epithelial stem cell cloning platform, IntelCell creates highly engineered “biological intelligent cells.” The process begins with precision gene-editing tools like CRISPR-Cas9 to engineer immune-evasive properties into our stem cells, significantly reducing allogeneic transplant rejection and enhancing long-term engraftment. Modular, standardized gene-control circuits are then incorporated, embedding functional gene modules with antiinflammatory, anti-fibrotic, or pro-regenerative activities. These modules are coupled with microenvironment-responsive sensors (e.g., responsive to hypoxia or inflammatory signals) and regulated by an externally controllable “master switch” (e.g., activated by a small molecule), enabling spatially and temporally controlled therapeutic intervention.
Once transplanted, these engineered cells can persistently monitor the pathological microenvironment and autonomously initiate targeted reparative programs, functioning as an in vivo “sense — decide — act” closed-loop system. This paradigm overcomes the limitations of traditional cell therapies, which often have limited functionality, transient activity, or lack controllability.
MIX0109 Tissue & Cell Rejuvenation Technology
Enhancing Cell Quality and Therapeutic Potential
Our MIX0109 technology is a breakthrough innovation in regenerative medicine and anti-aging, designed to counteract age-associated decline and restore the regenerative potential of tissue stem cells. Through a proprietary nine-component small-molecule combination, MIX0109 targets key epigenetic and metabolic mechanisms implicated in cellular aging, effectively resetting the “epigenetic clock” of cells.
MIX0109 has been shown to reduce senescence-associated secretory phenotype (SASP) activity, restore telomere stability, and activate endogenous regenerative pathways. Stem cells treated with MIX0109 exhibit improved proliferative capacity, extended expansion potential, and preserved differentiation competence, addressing key limitations of aged or senescent cells.
MIX0109 offers dual application value: (1) as a direct therapeutic intervention for aging-related degenerative diseases; and (2) as a critical process enhancement technology within our cell therapy pipeline — improving the quality, potency, and engraftment potential of REGEND-series cell products.
Chimera Chimeric Animal Model Technology
The Golden Standard for In Vivo Validation
Our Chimera platform is a globally leading in vivo functional validation system, serving as the critical bridge from laboratory research to clinical translation. It provides essential evidence of a cell product’s regenerative potential within a physiologically relevant, living organism.
This technology involves the precise transplantation of human stem cells, expanded using the R-Clone epithelial stem cell cloning platform, into immunodeficient animal models of human disease (e.g., pulmonary fibrosis, chronic kidney disease). These human cells can efficiently engraft, persist, and differentiate within the host’s injured tissue, forming structurally and functionally integrated chimeric tissue. Using advanced molecular tracing and imaging technologies, the Chimera platform enables comprehensive monitoring of cell fate and evaluation of regenerative activity, safety, and therapeutic effects in vivo.
REGEN-Wukong AI Platform
Data-Driven Predictive Analytics
REGEN-Wukong is an AI-based predictive platform that analyzes multimodal data from our clinical programs to help forecast how patients will respond to our cell therapeutic products. By integrating clinical indicators, lung function tests, imaging results, and cellular molecular profiles, the platform identifies patterns linked to treatment benefit and disease progression. It is designed to support physicians and researchers in selecting most suitable therapy for patients, predicting therapeutic outcomes, and optimizing clinical trial design.
From an application and commercialization perspective, REGEN-Wukong delivers value across multiple dimensions, including: (1) patient stratification and selection, identifying individuals most likely to respond to therapy; (2) prediction of therapeutic outcomes, enabling proactive clinical strategy adjustments; (3) clinical trial design optimization, improving development efficiency and reducing clinical risk; and (4) strategic decision support, informing indication expansion, product positioning, and portfolio planning.
Specialized Organ-Specific Validation Platforms
MiniLung Platform
This system utilizes lung progenitor cells and an advanced air-liquid interface (ALI) culture system to reconstruct a multicellular human proximal airway epithelium. The resulting structure recapitulates key physiological functions, including mucociliary clearance, providing a highly relevant model for studying lung disease mechanisms and epithelial repair.
MiniKidney Platform
Utilizing kidney stem cells, this platform efficiently generates three-dimensional “mini-kidney” organoids that contain multiple renal tubular cell types within a remarkably short time. MiniKidney offers a robust, reproducible, and cost-effective in vitro model for investigating chronic kidney disease mechanisms and evaluating regenerative therapeutic strategies.